Novartis

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

Retrieved on: 
Monday, December 5, 2022

She will lead the Company's clinical development program and provide medical oversight across all indications.

Key Points: 
  • She will lead the Company's clinical development program and provide medical oversight across all indications.
  • NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
    "The NRx team is excited to have attracted a clinician with deep experience as an investigator.
  • Dr. Carretta's wealth of knowledge will help drive our mission to develop a first-in-class lifesaving drug for suicidal depression and PTSD.
  • Prior to this role, Dr. Carretta served as the Vice President, Medical and Scientific Affairs at Pendulum Therapeutics.

Telix Announces Executive Leadership Appointments

Retrieved on: 
Sunday, December 4, 2022

MELBOURNE, Australia, Dec. 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.

Key Points: 
  • MELBOURNE, Australia, Dec. 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.
  • Telix also announces that Genevieve Ryan joins as Group Company Secretary, effective today, 5 December 2022.
  • Dr. Christian Behrenbruch, Telix Group CEO and Managing Director said, "These leadership appointments are a result of ongoing succession planning to ensure Telix has an optimal mix of skills and experience as we prepare to enter a new phase with a portfolio of multiple commercial products.
  • Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan.

Telix Announces Executive Leadership Appointments

Retrieved on: 
Sunday, December 4, 2022

MELBOURNE, Australia, Dec. 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.

Key Points: 
  • MELBOURNE, Australia, Dec. 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.
  • Telix also announces that Genevieve Ryan joins as Group Company Secretary, effective today, 5 December 2022.
  • Dr. Christian Behrenbruch, Telix Group CEO and Managing Director said, "These leadership appointments are a result of ongoing succession planning to ensure Telix has an optimal mix of skills and experience as we prepare to enter a new phase with a portfolio of multiple commercial products.
  • Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan.

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022

Retrieved on: 
Thursday, December 1, 2022

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globes 2022 Top Places to Work in the Largest Employer category.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globes 2022 Top Places to Work in the Largest Employer category.
  • Im immensely proud of our team as we reach our eighth consecutive year on Boston Globes Top Places to Work, said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam.
  • To be ranked first on the list two years running is a testament to our commitment to excellence.
  • Companies named to the Top Places to Work list are chosen by the people who best understand the workplace environment: the employees.

Mnemo Therapeutics Appoints Christine Foster, Ph.D. and Co-Founder Sebastian Amigorene, Ph.D. to Key Leadership Roles

Retrieved on: 
Wednesday, November 30, 2022

Mnemo also announced the appointment of Scientific Co-Founder Sebastian Amigorena, Ph.D. as Senior Vice President, Immunology.

Key Points: 
  • Mnemo also announced the appointment of Scientific Co-Founder Sebastian Amigorena, Ph.D. as Senior Vice President, Immunology.
  • "Christine brings a stellar history building meaningful value for biopharmaceutical companies by guiding business development and establishing strategic collaborations," said Mnemo Chief Executive Officer Robert LaCaze.
  • "I am thrilled to contribute to the science and innovation taking place at Mnemo Therapeutics," Foster said.
  • To learn more, visit https://mnemo-tx.com and follow Mnemo Therapeutics on Twitter (@MnemoTx) and LinkedIn.

The Global Addison's Disease Therapeutics Market is expected to grow by $442 mn from 2023-2027, accelerating at a CAGR of 6.93% during the forecast period

Retrieved on: 
Wednesday, November 30, 2022

Key Points: 
  • Also, the availability of clinical guidelines and redefined pathophysiology will lead to sizable demand in the market.
  • The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • Also, Addisons disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

Retrieved on: 
Wednesday, November 30, 2022

FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022.

Key Points: 
  • FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022.
  • Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology.
  • As we prepare for the approval of iopofosine, his professional background is ideally suited for our newly created position of chief commercial officer and we look forward to his leadership, said James Caruso, president and chief executive officer of Cellectar.
  • Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer.

Global alliance of heart patient organizations unveils new Global Cholesterol Action Plan to prioritize unhealthy cholesterol as a main public health issue

Retrieved on: 
Wednesday, November 30, 2022

GALWAY, Ireland, Nov. 30, 2022 /PRNewswire/ -- The Global Heart Hub has today launched its Global Cholesterol Action Plan to reduce the impact of unhealthy cholesterol levels .

Key Points: 
  • GALWAY, Ireland, Nov. 30, 2022 /PRNewswire/ -- The Global Heart Hub has today launched its Global Cholesterol Action Plan to reduce the impact of unhealthy cholesterol levels .
  • Presented at their annual UNITE Summit , the Action Plan follows and builds upon the World Heart Federation's Cholesterol Roadmap released in October.
  • The Global Heart Hub aims to implement change in the way unhealthy cholesterol levels are prevented and managed at local levels to reduce ASCVD .
  • The new Action Plan outlines four clear goals to ensure unhealthy cholesterol levels are addressed as a public health priority: build alliances, raise public awareness, activate alliances, and improve high cholesterol detection and management.

Global alliance of heart patient organizations unveils new Global Cholesterol Action Plan to prioritize unhealthy cholesterol as a main public health issue

Retrieved on: 
Wednesday, November 30, 2022

GALWAY, Ireland, Nov. 30, 2022 /PRNewswire/ -- The Global Heart Hub has today launched its Global Cholesterol Action Plan to reduce the impact of unhealthy cholesterol levels .

Key Points: 
  • GALWAY, Ireland, Nov. 30, 2022 /PRNewswire/ -- The Global Heart Hub has today launched its Global Cholesterol Action Plan to reduce the impact of unhealthy cholesterol levels .
  • Presented at their annual UNITE Summit , the Action Plan follows and builds upon the World Heart Federation's Cholesterol Roadmap released in October.
  • The Global Heart Hub aims to implement change in the way unhealthy cholesterol levels are prevented and managed at local levels to reduce ASCVD .
  • The new Action Plan outlines four clear goals to ensure unhealthy cholesterol levels are addressed as a public health priority: build alliances, raise public awareness, activate alliances, and improve high cholesterol detection and management.

Aequus Reports Third Quarter 2022 Financial Highlights

Retrieved on: 
Wednesday, November 30, 2022

VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (Aequus or the Company), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reported financial results for the quarter ended September 30, 2022 (Third Quarter 2022) and associated Company developments.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (Aequus or the Company), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reported financial results for the quarter ended September 30, 2022 (Third Quarter 2022) and associated Company developments.
  • Aequus reported $268,970 in promotional services and product sales revenue during Third Quarter 2022 compared to revenue of $669,000 generated during the three months ended September 30, 2021 (Third Quarter 2021).
  • Net losses increased by 31% in Third Quarter 2022 compared to the same period last year, with the Third Quarter 2022 net loss of $500,471 versus a $381,536 loss in Third Quarter 2021.
  • Highlights from the quarter are as follows:
    Sales and marketing costs for Third Quarter 2022 were $506,230 compared to $551,966 in Third Quarter 2021, a decrease of $45,736 or 8%.